Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 21, 2017. The report announces a change in the composition of the Company's Board of Directors, specifically the appointment of Dr. Laurie Glimcher as a Non-Executive Director and Scientific and Medical Expert, effective September 1, 2017.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a corporate governance announcement regarding board appointments.
Material Changes
- Board Appointment: Dr. Laurie Glimcher has been appointed to the Board of Directors.
- Role Designation: Dr. Glimcher is designated as a Scientific and Medical Expert and will join the Science and Audit & Risk Committees.
- Independence: The Board has determined Dr. Glimcher to be an independent Non-Executive Director in accordance with the UK Corporate Governance Code.
Management Commentary and Compensation
Philip Hampton, Chairman of GSK, stated that Dr. Glimcher brings a wealth of expertise in scientific and medical innovation and public health. Her background includes serving as CEO and President of the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
Compensation Structure:
- Standard annual fees: £85,000.
- Additional fees for Scientific and Medical Expert duties: £30,000.
- At least 25% of fees will be paid in Ordinary Shares allocated to a share account.
Risks and Forward-Looking Statements: The filing includes a standard cautionary statement that forward-looking projections are subject to risks and uncertainties, referencing the "Risk factors" section of the 2016 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Dr. Laurie Glimcher's start date on the Board is September 1, 2017.
- Dr. Glimcher will serve on the Science and Audit & Risk Committees.
- Total annual compensation for the role is £115,000, with a significant portion payable in company stock.
- The filing confirms no further disclosures are required under Listing Rule 9.6.13R regarding this appointment.